Table 3.

Summary of in vivo activity for αCD30 glucuronide–tubulysin DAR 4 ADCs

ADC:αCD30-7αCD30-8αCD30-9
payload:Tub(OAc)Tub(OEt)Tub(OiVal)
XenograftDose (mg/kg)n/groupCRaCuresCRCuresCRCures
CD30+, MDR L540cy HL0.1560010
0.361122
0.2561111
0.566443
CD30+, MDR+ DEL/BVR ALCL155521
1.2611
1:1 CD30+:CD300.55315443
Karpas/KarpasBVR bystander model1.55304354
  • aComplete regression observed following ADC treatment and includes durable and transient complete regressions.